• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Flu Patients Get Better Sooner With Oseltamivir, Pragmatic Trial Shows Flu Patients Get Better Sooner With Oseltamivir, Pragmatic Trial Shows
A study from Europe provides estimates of the likely benefits of adding oseltamivir to usual care for patients with influenza-like illness.Reuters Health Information
Source: Medscape Allergy Headlines - December 20, 2019 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology
Conclusions: Human challenge studies and systems biology approaches are important tools that should be used in concert to advance our understanding of influenza infection and provide targets for novel therapeutics and immunizations. Introduction Although influenza virus was recognized as an important pathogen over a century ago, influenza continues to cause a significant burden of disease. In the United States alone, it's estimated that in the 2017–2018 season there were 959,000 hospitalizations related to influenza illness, and 79,400 deaths (CDC, 2018). Worldwide, WHO estimates that annual influen...
Source: Frontiers in cellular and infection microbiology - April 16, 2019 Category: Microbiology Source Type: research

Oseltamivir Safely Reduces Disease Duration in Kids With Influenza Oseltamivir Safely Reduces Disease Duration in Kids With Influenza
Oseltamivir is safe and effective for treating children with influenza, according to a systematic review.Reuters Health Information
Source: Medscape Allergy Headlines - December 11, 2017 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news

Dampness Can Promote the Influenza A Virus and Worsen Its Prognosis by Upregulating the TLR7 Signaling Pathway.
Conclusions • The study suggests that dampness can promote the IAV infection and worsen its prognosis by upregulating the TLR7 signaling pathway. PMID: 28646802 [PubMed - as supplied by publisher]
Source: Alternative Therapies in Health and Medicine - June 23, 2017 Category: Complementary Medicine Authors: Li D, Huachong X, Peng P, Ke Z, Jiao N, Xianlin W, Bin Y, Jia C, Xiaoyin C Tags: Altern Ther Health Med Source Type: research

Infection in Severe Asthma Exacerbations and Critical Asthma Syndrome
Abstract In chronic persistent asthma and severe acute exacerbations of bronchial asthma, infectious agents are the predominant triggers that drive disease and airway pathobiology. In acute exacerbations of bronchial asthma (AEBA) including near fatal and fatal asthma, viral agents, particularly human rhinovirus-C, respiratory syncytial virus and influenza A appear to be the more prevalent and recurring threats. Both viral, and to a lesser extent bacterial agents, can play a role, and co-infection may also be present and worsen prognosis in hospitalized patients, placing a portion at risk for critical asthma synd...
Source: Clinical Reviews in Allergy and Immunology - January 24, 2015 Category: Allergy & Immunology Source Type: research

Altmetric tracks the buzz around scholarly articles: You can make a difference
Altmetric tracks the buzz around scholarly articles - see an example: http://bit.ly/1lF9KtR You can make a difference. See how my blog contributed to one of highest ever scores in this journal for this article (ranked #7 of 972): Children with severe asthma have 32 times higher risk for developing COPD http://buff.ly/1oIJ3FHHere is the blog post: Allergy Notes: What are the top 3 asthma articles for March 2014? Vote here http://bit.ly/1hjZ6JuThe article will be included in the next edition of What Is New In Small Airways Researchhttp://www.worldallergy.org/small_airways_group/reviews/The beautiful flower of Inter...
Source: Clinical Cases and Images - April 11, 2014 Category: Journals (General) Tags: Social Media Twitter Source Type: news

Double dose of antiviral drug offers no added benefit in severe influenza
(Wellcome Trust) Giving double doses of the antiviral drug oseltamivir, or Tamiflu, offers no clinical or virological advantages over a standard dose for patients admitted to hospital with severe influenza infection, according to a randomized trial published today and funded by the Wellcome Trust, US National Institute of Allergy and Infectious Diseases and the Singapore National Medical Research Council.
Source: EurekAlert! - Infectious and Emerging Diseases - May 30, 2013 Category: Infectious Diseases Source Type: news

Oseltamivir Pharmacology in Young Children: A Commentary.
Abstract Oseltamivir is listed by the World Health Organization as an essential drug for the treatment and prophylaxis of both seasonal and pandemic influenza. Since influenza mortality is highest in neonates and infants, optimal dosing of oseltamivir in this high risk population is of utmost public health concern. To date, only two major clinical trials have been conducted investigating oselatmivir exposure and exposure/response in neonates and infants. The first study was a prospective, open label pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir in a total of 87 young children less than 2 yea...
Source: Infectious Disorders Drug Targets - May 8, 2013 Category: Infectious Diseases Authors: Kamal MA Tags: Infect Disord Drug Targets Source Type: research